Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The dilemma of carboplatin-associated hypersensitivity reactions in ovarian cancer management.

× No keyword cloud information.

7 in total

1. Usefulness of desensitization protocol for a carboplatin hypersensitivity reaction during docetaxel-carboplatin therapy for recurrent ovarian cancer: Case report.

Authors: Tadahiro Shoji; Eriko Takatori; Yoshitaka Kaido; Seisuke Kumagai; Satoshi Takeuchi; Akira Yoshizaki; Toru Sugiyama
Journal: Oncol Lett Date: 2010-09-23 Impact factor: 2.967

Review 2. Presentation and Diagnosis of Hypersensitivity to Platinum Drugs.

Authors: Joana Caiado; Mariana Castells
Journal: Curr Allergy Asthma Rep Date: 2015-04 Impact factor: 4.806

3. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.

Authors: Maurie Markman; James Moon; Sharon Wilczynski; Ana Maria Lopez; Kendrith M Rowland; David P Michelin; Victor J Lanzotti; Garnet L Anderson; David S Alberts
Journal: Gynecol Oncol Date: 2009-12-30 Impact factor: 5.482

7. Hypersensitivity following Retreatment with Carboplatin a Decade after Completion of Primary Platinum-Based Chemotherapy.

Authors: Laura Williams; Maurie Markman
Journal: Case Rep Oncol Date: 2009-02-20

7 in total

The dilemma of carboplatin-associated hypersensitivity reactions in ovarian cancer management.

1. Usefulness of desensitization protocol for a carboplatin hypersensitivity reaction during docetaxel-carboplatin therapy for recurrent ovarian cancer: Case report.

Review 2. Presentation and Diagnosis of Hypersensitivity to Platinum Drugs.

3. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.

Review 4. Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis.

5. Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies.

6. Current awareness: pharmacoepidemiology and drug safety.

7. Hypersensitivity following Retreatment with Carboplatin a Decade after Completion of Primary Platinum-Based Chemotherapy.